期刊文献+

高值血清CA19-9稀释测定的影响因素研究 被引量:2

Research on The Influencing Factor of High Serum CA19-9 Dilution Assay
下载PDF
导出
摘要 探讨高值血清CA19-9稀释后测定的结果与临床影响因素。对高值血清CA19-9用不同的稀释液(去离子水,Dil稀释液,健康人混合低值血清),不同稀释倍数(1∶2;1∶5;1∶10;1∶20)经手工稀释测定和仪器自动稀释检测。结果表明:用Dil稀释液进行稀释,手工法和仪器自动稀释法呈明显正相关;3种稀释液稀释高值血清CA19-9均无显著性差异(P>0.05);各稀释物在不同的稀释倍数之间结果无显著性差异(P>0.05)。其中试剂盒检测线性范围内高值血清CA19-9稀释测定结果与直接测定值有较好的相关性。用3种稀释液可以满足临床稀释要求,而仪器自动稀释法更有助于操作的自动化,减少人为操作的随机误差。 To explore the diluted results and clinical influencing factor of high CA19-9 in human serum.The human high serum CA19-9 were measured by deionized water,Dil,and low serum,and by different dilution ratio(1∶2,1∶5,1∶10,1∶20) in manual and instrumental automatic dilution.There was a positive correlation between manual and instrumental dilution with Dil.There was no significant difference in three different diluents and dilution ratio in high serum CA19-9.The three diluents were suitable for clinical analysis,and Dil was more favorable for automation in laboratory and for preventing from accidental error.
出处 《标记免疫分析与临床》 CAS 2011年第4期265-267,共3页 Labeled Immunoassays and Clinical Medicine
基金 国家科技支撑计划(2009BAI86B05)
关键词 血清 CA19-9 稀释液 稀释倍数 稀释方法 Serum CA19-9 Diluent Dilution ratio Dilution method
  • 相关文献

参考文献5

二级参考文献14

  • 1李江,刘金玲,董作亮,高硕.3种检测血管紧张素-Ⅱ放射免疫试剂盒的比较[J].天津医药,2004,32(12):769-771. 被引量:2
  • 2Trenti T. Evidence-based laboratory medicine as a tool for continuous professional improvement. Clin Chim Acta, 2003,333 : 155-167.
  • 3Trenti T, Canali C, Scognamiglio A. Clinical Governance and evidence-based laboratory medicine. Clin Chem Lab Med, 2006, 44:724-732.
  • 4Kawai T. A perspective toward EBD/EBLM. Rinsho Byori, 2003, 51:669-672.
  • 5National Committee for Clinical Laboratory Standards. Evaluation of precision performance of clinical chemistry devices;Approved guideline NCCLS, Document EPS-A. Wayne, PA : NCCLS, 1999 : 1-42.
  • 6CLSI. Evaluation of the linearity of quantitative measurement procedures: a statistical approach; Proposed Guideline Second Edition. CLSI, document EP6-A. U S A CLS1:2003 : 1-47.
  • 7CLSI. Laboratory Statistics-Standard Deviation, Approved guideline CLSI, document , EP13-R. U S A : CLSI, 1995 : 1-20.
  • 8Yamaguchi K, Sawada T, Naraki T, et al. Detection of boma disease virus-reactive antibodies from patients with psychiatric disorders and from horses by electrochemiluminescence immunoassay. Clin Diagn Lab Immunol, 1999,6:696-700.
  • 9Forest JC, Masse J, Lane A. Evaluation of the analytical performance of the Boehringer Mannheim Elecsys 2010 immunoanalyzer. Clin Biochem, 1998,31:81-88.
  • 10Butler SA, Staite EM, Iles RK. Reduction of bladder cancer cell growth in response to hCGbeta CTP37 vaccinated mouse serum. Oncol Res,2003,14:93-100.

共引文献43

同被引文献23

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部